Literature DB >> 28555936

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report.

M J Company-Albir1, J Ruíz-Ramos2, A Solana Altabella1, M R Marqués-Miñana1, C Vicent2, J L Poveda1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Levetiracetam is used in the treatment of some forms of epilepsy. In renal impairment and patients on chronic haemodialysis, dose adjustment is required. We report a case. CASE DESCRIPTION: This case report describes a woman on levetiracetam treatment who presented with generalized tonic-clonic seizures during a haemodialysis session. We report on treatment adjustment and on the impact of dialysis on levetiracetam levels. WHAT IS NEW AND
CONCLUSION: Haemodialysis reduces serum levetiracetam concentration and can lead to subtherapeutic levels. Close monitoring is necessary when dialysis is used on patients receiving anticonvulsant drugs that are extensively eliminated by the procedure.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  dialysis; epilepsy; haemodialysis; levetiracetam; monitoring; pharmacokinetics; seizures

Mesh:

Substances:

Year:  2017        PMID: 28555936     DOI: 10.1111/jcpt.12568

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  1 in total

1.  Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis.

Authors:  Patrick M Wieruszewski; Kianoush B Kashani; Alejandro A Rabinstein; Erin Frazee
Journal:  Neurocrit Care       Date:  2018-04       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.